



NewLink Genetics Corporation  
Investor Relations Department  
2503 South Loop Drive  
Ames, IA 50010  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

## Company Profile

---

Founded in 1999, NewLink Genetics is an immuno-oncology company focused on discovering and developing novel products for the treatment of cancer. The drug discovery and development teams at NewLink Genetics are relentlessly pursuing a wide range of immuno-oncology portfolio candidates with the potential to change the oncology landscape. NewLink Genetics' portfolio includes two small-molecule product candidates currently in clinical development. These product candidates inhibit the IDO pathway, a key immuno-oncology target, and focus on breaking the immune system's tolerance to cancer.

## Press Releases [\[ View all \]](#)

---

*Jul 27, 2017*

[NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802](#)

*Jul 10, 2017*

[NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs](#)

*Jul 7, 2017*

[NewLink Genetics to Host Its Second Quarter 2017 Financial Results Conference Call on July 28, 2017](#)

*Jun 23, 2017*

[Positive Phase 1b Data for NewLink Genetics' IDO Pathway Inhibitor, Indoximod, in Combination with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia \(AML\) Presented at the European Hematologic Association \(EHA\) Congress in Madrid, Spain](#)

*Jun 8, 2017*

[NewLink Genetics to Regain Rights to GDC-0919](#)

## Upcoming Events [\[ View all \]](#)

---

*Jul 28, 2017 8:30 AM ET*

[Second Quarter 2017 Earnings Conference Call](#)

## Financials [\[ View all \]](#)

---

[First Quarter Financial Results](#)

*Mar 6, 2017*

[Annual Report \(10-K\)](#)

*Mar 31, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 5, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 8, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 5, 2016*

[Quarterly Report \(10-Q\)](#)